Condition: Lynch Syndrome · Lynch Syndrome I · Lynch Syndrome II · Sponsor: San Raffaele University
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM. Despite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching as high as 41-36% among MLH1 carriers, regardless of ethnic background. The development of colorectal cancer despite surveillance is an unresolved question. Therefore, there is an unmet need for effective cancer prevention strategies.
This description comes directly from the study's public registry record.
Giulia Martina Cavestro, MD, PhD · 0226436303 · cavestro.giuliamartina@hsr.it
Alessandro Mannucci, MD · 0226436303 · mannucci.alessandro@hsr.it
Always discuss trial participation with your own doctor first.
| Beckman Research Institute at City of Hope | Monrovia, California, United States | Recruiting |
| Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital | Milan, Lombardy, Italy | Recruiting |
| Dipartimento di Chirurgia Oncologica e Dipartimento di Oncologia Sperimentale Istituto Nazionale Tumori | Milan, MI, Italy | Recruiting |
| Dipartimento di controllo qualità e rischio chimico biologico, AOOR Villa Sofia Cervello | Palermo, PM, Italy | Recruiting |
| Chirurgia Generale, Azienda Ospedaliero Universitaria di Cagliari | Cagliari, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06708429